fluconazole has been researched along with Adnexitis in 3 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Adnexitis: Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).
Excerpt | Relevance | Reference |
---|---|---|
"One hundred and sixty five women with diagnosis of pelvic inflammatory disease were randomized into three equal groups getting ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1), a kit containing fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2) and Doxycycline 100mg twice daily and metronidazole 200 mg thrice daily for seven days (Group 3)." | 9.10 | Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. ( Arora, R; Batra, S; Malhotra, M; Sharma, JB; Sharma, S, 2003) |
"One hundred and sixty five women with diagnosis of pelvic inflammatory disease were randomized into three equal groups getting ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1), a kit containing fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2) and Doxycycline 100mg twice daily and metronidazole 200 mg thrice daily for seven days (Group 3)." | 5.10 | Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. ( Arora, R; Batra, S; Malhotra, M; Sharma, JB; Sharma, S, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ressel, GW | 1 |
Malhotra, M | 1 |
Sharma, JB | 1 |
Batra, S | 1 |
Arora, R | 1 |
Sharma, S | 1 |
Sing, Y | 1 |
Ramdial, PK | 1 |
Ibrahim, T | 1 |
1 trial available for fluconazole and Adnexitis
Article | Year |
---|---|
Ciprofloxacin-tinidazole combination, fluconazole- azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Azithromycin; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Female; Fluc | 2003 |
2 other studies available for fluconazole and Adnexitis
Article | Year |
---|---|
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID.
Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic | 2002 |
Cryptococcosis masquerading as a tuboovarian abscess.
Topics: Abscess; Adult; Antifungal Agents; Cryptococcosis; Cystadenocarcinoma, Mucinous; Diagnosis, Differen | 2008 |